Sciety

🗞️ Hot off the press! In our latest newsletter, we analyse key trends from FDA's recent drug approvals, including breakthroughs in gene editing, precision medicine, and cell therapy for solid tumours. We also acknowledge Sciety's 10-year journey in the Nordic life science ecosystem and share a fascinating breakthrough in complete brain mapping. Plus, exciting updates from some of our portfolio companies: Predicare AB, NEOGAP Therapeutics AB, Capitainer, and Elypta. Read the full newsletter to stay up-to-date on the latest updates from Sciety and the life science ecosystem. #LifeScience #Innovation #Healthcare #NordicInnovation

🔬 The rapid advancement of AI is expected to significantly transform healthcare, and implementation is gaining momentum. A recent McKinsey survey reveals that more than 70% of participants from healthcare organisations have either already implemented or are implementing generative AI-based solutions. The greatest potential value lies in clinician and care provider productivity, specifically: ➡️ Improving speed and reliability of diagnosis ➡️ Enhanced treatment planning ➡️ Efficient care flows ➡️ Better forecasting of patient influx At Sciety, we encounter many Nordic companies leveraging generative AI in products and services aimed at improving healthcare efficiency. We meet companies using AI in products for patient risk stratification to ensure appropriate treatment interventions and predict the most suitable treatment for each patient, as well as solutions focused on optimising healthcare processes and operations management. The global AI in healthcare market size was estimated at USD 19 billion in 2023 and is expected to grow at an annual rate of 38.5% through 2030. 💡 Want to receive life science insights like these straight to your inbox? Sign up for Sciety's newsletter to receive news, exclusive event invitations and updates about upcoming investment opportunities: https://lnkd.in/dmWn7y4s #HealthcareInnovation #AI #NordicHealthTech

🎉 Celebrating a decade in Nordic life science! On this day 10 years ago, Sciety was officially registered as a company. For the past decade, we've had the privilege of working alongside remarkable scientists and entrepreneurs who are advancing healthcare through innovations in life science and digital health. Our journey so far: ✅ Over 1 billion SEK invested ✅ 26 innovative portfolio companies ✅ 9 successful exits through acquisitions or IPOs ✅ Countless life science innovations being developed into impactful solutions Thank you to all our partners, investors, portfolio companies and team members who have contributed to developing the Nordic life science ecosystem together with us over the past decade ⭐️ Read more about our journey and upcoming plans in our latest article: https://lnkd.in/gcnt_7tE #LifeScience #HealthTech #VentureCapital

🔬Another big step forward for our portfolio company NEOGAP Therapeutics AB! Neogap Therapeutics - developing personalised cancer immunotherapy using the patient's own cells - has entered a strategic manufacturing partnership with the CDMO NorthX Biologics. The partnership focuses on optimising and scaling production of Neogap's personalized pTTL therapy, currently in a Phase I/II clinical trial assessing safety and tolerability in patients with advanced colorectal cancer. By combining Neogap's innovative approach with NorthX Biologics' manufacturing expertise, this collaboration aims to establish a cost-effective and scalable production setup that will support both future large-scale clinical trials and broader patient access. The collaboration is supported by the European Innovation Council (EIC) Accelerator and marks an important step in Neogap's journey. Congratulations team Neogap on this significant milestone!  #LifeScience #Immunotherapy #VentureCapital

🚀 Exciting news from our portfolio company Capitainer! Capitainer has just launched the innovative Capitainer®SEP10 sampling card, designed for easy and reliable at-home blood sampling. Capitainer®SEP10 is revolutionising diagnostics and research with a streamlined sampling process: ✅ Measurement of exact blood volume ✅ Separation of blood cells from the liquid ✅ No need for a trained phlebotomist ✅ Indication of sample success ✅ No need for syringes, gloves, or specialized equipment Capitainer®SEP10 is now ready to impact healthcare diagnostics across the U.S. and EU. This cutting-edge tool has already drawn the attention of the research community, including Professor Henrik Zetterberg, who calls it a game-changer for neurodegenerative disease diagnostics. Congratulations to Capitainer on this remarkable launch! We look forward to seeing the positive impact of this new technology. #LifeScience #HealthcareInnovation #Diagnostics #MedTech 

👋 Meet us at BIO-Europe 4-6 November! We're looking forward to attending BIO-Europe in Stockholm next week. Andreas Lindblom, Marcus Hjort, MD, PhD, Nick Roelofs, and Tor Sander will be there to connect with interesting life science companies and other investors within life science.    Drop us a message or reach out through the partnering portal to schedule a meeting - we would be happy to connect!   #BIOEurope #lifescience #venturecapital

🍁 Autumn is officially here and with that comes a fresh edition of our newsletter Sciety News & Insights. This month we explore the rapid adoption of generative AI in healthcare and the potential it holds for improving patient outcomes and operational efficiency. Additionally, we take a closer look at the groundbreaking discovery of microRNA, which was recognised with this year's Nobel Prize in Physiology or Medicine. We also share the latest updates from some of our portfolio companies: Akiram Therapeutics, Elypta, Capitainer, Encare - Enhancing ERAS®, NEOGAP Therapeutics AB, and Synartro.   Read the full newsletter to stay up-to-date on the latest updates from Sciety and the life science ecosystem.

🚀 New report reveals remarkable growth in Swedish life science industry! The latest statistics from Vinnova show that Swedish life science companies are experiencing significant export growth and expansion. ✅ Exports have increased across all top 15 export markets ✅ Singapore stands out with an astounding 2,610% export growth (from SEK 0.8B to 20.9B) between 2011-2014 and 2019-2022 ✅ MedTech leads the Swedish life science sector in terms of number of companies, spanning everything from medical devices and implants to surgical tech and eHealth solutions. The report's special focus on deep tech reveals how groundbreaking technologies originally developed outside healthcare - such as laser, AI, and nanotechnology - are finding revolutionary applications in clinical care. These roughly 60 identified deep tech companies, predominantly founded by PhDs and professors, are combining multiple advanced technologies like synthetic biology, AI, and nanotechnology to drive the next breakthrough in patient care. As a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region - we're excited to see Sweden maintaining its position as a global innovation hub, ranking no. 2 in the Global Innovation Index! Want to take part in Scietys mission to build the future through impactful life science investments? Join Sciety Venture Partners and be the first to know about investment opportunities in the Nordics: https://lnkd.in/dmZkr6k7 #LifeScience #SwedishInnovation #Investments

We have an exciting update from our portfolio company Akiram Therapeutics – their drug candidate has been cleared to start phase 1 clinical trial! 🎉 Akiram Therapeutics is developing a new type of targeted radiotherapy for cancer and the drug candidate 177Lu-AKIR001 has now received approval from the Swedish Medical Products Agency to initiate a phase 1 study. The trial will be led by Karolinska University Hospital, overseeing all clinical aspects including patient recruitment and trial management.   This is a key milestone for Akiram's development of cancer treatment and could offer new hope for patients with hard-to-treat tumours.   Congratulations to the team!   #LifeScience #Oncology #CancerResearch

At Sciety, we are passionate about supporting the companies we have invested in and celebrating their progress as they make an impact in their respective markets. A great example is Encare - Enhancing ERAS®, whose innovative solutions have helped Sykehuset Østfold in Norway achieve remarkable recognition for its ERAS® (Enhanced Recovery After Surgery) program. The hospital has earned the prestigious Norwegian Forbedringsprisen award and ERAS® Center of Excellence status. Through Encare’s EIAS and EIP solutions, Sykehuset Østfold has significantly improved patient outcomes in colorectal surgeries, reducing complications and shortening hospital stays. The hospital’s efforts have not only enhanced care quality but also resulted in major cost savings, with NOK 47 million saved annually. This demonstrates the powerful role digital health solutions can play in transforming healthcare efficiency and quality. #HealthTech #Healthcare #ERAS